Lonza reports a successful 2008
Wednesday, 28.01.2009

Lonza reports a successful 2008

The Basel pharmaceutical supplier Lonza ended 2008 with a record performance.

In 2008, Lonza increased its sales by 2.3 percent to almost three billion francs. As for its net income, the Basel company even posted a 39.2 percent growth to 419 million francs. The main reason for these positive figures lies in a book profit of 90 million francs from the sale of its former polymer subsidiary Polynt.


Lonza CEO Stefan Borgas also expressed his satisfaction with the performance of the operating business. The life sciences portfolio that has been built up in the last few years, he said, proved crisis-resistant last year. While the recession certainly left its mark in a few business areas of Lonza, the company nevertheless profited from the trend towards greater outsourcing among its pharmaceutical clients.


Borgas places a lot of hope in the new business model with complex pipeline contracts for the development and manufacture of biological active substances. After conclusion of the first agreement with Novartis, Lonza is now negotiating with five other companies.

The CEO described the latest agreement concluded with the Israeli generics producer Teva for the manufacture of so-called biosimilars as a "most important milestone". This agreement, he said, secures for Lonza not only part of the production margin, but also part of the pharmaceuticals margin with biotech generic medicines.


For further information, go to www.lonza.com